Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

PHAT

$5.742.96%-0.175

Vorbörslich: 5.70-0.04 -0.70%

Phathom Pharmaceuticals Inc (PHAT)

Date: O: H: L: C: Vol:

Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten

Phathom Pharmaceuticals Reports Q3 2026 Revenue of $84.7M with Reduced Net Loss - Kalkine Media

Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript - Benzinga

Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates - Yahoo Finance

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update - WBOC TV

Form 8K Phathom Pharmaceuticals Inc For: 26 October By Investing.com - Investing.com UK

Comments on the FDA’s VOQUEZNA docket close November 23, 2026, Phathom (PHAT) says. - Stock Titan

Phathom Pharmaceuticals Provides Update on FDA Litigation - GlobeNewswire Inc.

Phathom Pharmaceuticals reports lawsuit over Voquezna exclusivity By Investing.com - Investing.com Nigeria

Phathom Pharmaceuticals reports lawsuit over Voquezna exclusivity - Investing.com

Form 8K Phathom Pharmaceuticals Inc For: 23 October By Investing.com - Investing.com Australia

Phathom Pharmaceuticals, Inc. - Common Stock (Nasdaq:PHAT) Stock Quote - FinancialContent

Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA - GlobeNewswire Inc.

Phathom Pharmaceuticals, Inc. (PHAT) Stock Price, News, Quote & History - Yahoo! Finance Canada

Phathom Pharmaceuticals to Host Third Quarter 2026 Financial Results Webcast on October 29 - Quiver Quantitative

Jefferies cuts Phathom Pharmaceuticals price target on 2027 outlook - Investing.com

Phathom Pharmaceuticals Highlights New Cost-Effectiveness - GlobeNewswire

Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026 - Yahoo! Finance Canada

Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com - Investing.com UK

For tax withholding, Phathom (PHAT) CFO surrenders 13,485 shares at $6.78 each. - Stock Titan

Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com - Investing.com Nigeria

Ten shares will combine into one Monday; owners' percentage stakes stay the same except for fractional shares. - Stock Titan

BXP Director Julie Richardson Purchases 409.1 Phantom Stock Units - Kalkine Media

45,000 shares are proposed for sale at Spyre Therapeutics (SYRE), following two earlier sales. - Stock Titan

Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Canada

Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD By Investing.com - Investing.com South Africa

Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria

Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD - Investing.com UK

Tarsus Pharmaceuticals, Inc. (TARS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Phathom Pharmaceuticals Initiates Phase 3 Study of VOQUEZNA for As-Needed Treatment of Non-Erosive GERD - Quiver Quantitative

Heartburn medicine taken only when symptoms strike is being tested in a new study. - Stock Titan

Silvia, Inc. Common Stock (SVIA) Historical Data - Nasdaq

Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com UK

Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily

Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan

PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Yahoo Finance

Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com South Africa

Phathom Pharmaceuticals targets gastroenterolog... - Pluang

PHAT Initiates Coverage On Leerink Partners -- Rating Set to Mar - GuruFocus

Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT) - Seeking Alpha

Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com Canada

Phathom at Cantor conference: growth, access and new uses - Investing.com

PHAT Looks 63.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus

Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10 - Moomoo

Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT - marketscreener.com

PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Stocktwits

Phathom Pharmaceuticals Stock Price Forecast. Should You Buy PHAT? - StockInvest.us

PHAT stock holds near 9 dollars as Q2 loss narrows and revenue rises - ad-hoc-news.de

PHAT stock trades quietly as Phathom Pharmaceuticals prepares next data releases - ad-hoc-news.de

Price-Driven Insight from (PHAT) for Rule-Based Strategy - Stock Traders Daily

Phathom Pharmaceuticals to present at 2026 Cantor and HCWCO investment conferences - Traders Union

Ähnlich wie PHAT

APMD$15.062.21%

NVCT$19.340.83%

DBVT$10.1111.71%